Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21922352 | 0.84 | GAA (0.53) | GAALMNAHTTALDH1A1 | |
| SCHEMBL21922388 | 0.79 | ENPP2 (0.42) | MAOBGAAALDH1A1 | |
| SCHEMBL21923113 | 0.75 | ENPP2 (0.46) | GAA | |
| SCHEMBL13548218 | 0.74 | HTT (0.42) | HTTALDH1A1 | |
| SCHEMBL21923115 | 0.74 | LOX (0.49) | GAAALDH1A1 | |
| SCHEMBL21923110 | 0.74 | GABRG2 (0.46) | MAOB | |
| SCHEMBL21922353 | 0.71 | ENPP2 (0.46) | GAA | |
| SCHEMBL21922389 | 0.70 | ENPP2 (0.46) | — | |
| SCHEMBL10220140 | 0.69 | NNMT (0.41) | GAALMNAHTTALDH1A1 | |
| SCHEMBL2243975 | 0.69 | MAOB (0.45) | MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-19 | — | — | US | disclosed |
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-19 | — | — | US | disclosed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | MAOB 3020/4885GAA 436/4885TPSAB1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.